Skip to content

Addiction research published in 2025

Page 5 of 8: studies 81 to 100 of 156, newest first. Back to the addiction overview

Studies

THE ROLE OF REPETITIVE DHIKR AS A SPIRITUAL THERAPY FOR ADDICTION RECOVERY

International Journal of Education, Psychology and Counseling June 5, 2025 Rozeeda Kadri, Zaifuddin Md Rasip

This decade of spiritual meditation is heatedly being discussed among researchers to improve the recovery models of substance addictions such as drugs, marijuana, alcohol and similar existing by incorporating spiritual aspects into a biopsychosocial model. Therefore, the purpose of this paper is to propose a model of substance abuse recovery that needs to be developed so that current patterns...

A Case Series Demonstrating the Feasibility of Microdosing as a Bridging Method to Enable a Comfortable and Effective Transition From Prescribed Methadone to Buprenorphine ORT (Opiate Replacement Therapy), Without Initial Methadone Dose Reduction or Cessation, in UK Community Addiction Settings

BJPsych Open June 1, 2025 Zelda Summers, Jennie Rankine, Stuart Fisher

Aims: For patients prescribed methadone wishing to access buprenorphine ORT, the current practice is to reduce the methadone dose to 30/40 ml and cessation of methadone for 48 hrs prior to the switch. This exposes these patients to risk of psychological, physical distress or relapse into non-prescribed opiate use. Using guidance published by the Canadian Journal of Addiction we adapted this to...

The therapeutic effects of psychedelics for opioid use disorder: A systematic review of clinical studies.

Psychiatry Research June 1, 2025 Jeremy Weleff, Alejandra Pulido-Saavedra, Ardavan Mohammad Aghaei et al. 4 citations

Opioid-related overdose deaths have reached record high levels, and novel treatments for opioid use disorder (OUD) are needed. The three United States Food and Drug Administration (FDA)-approved medications for OUD function primarily at the mu-opioid receptor. While these remain the gold-standard treatment for OUD, they have shortcomings and treatment options separate from the opioid receptor...

Efficacy and safety of psilocybin for the treatment of substance use disorders: A systematic review.

Neuroscience & Biobehavioral Reviews June 1, 2025 Shakila Meshkat, Gunjan Malik, Richard J. Zeifman et al. 11 citations

Psilocybin, a serotonergic psychedelic, may have therapeutic benefits for Substance Use Disorders (SUDs), but its overall efficacy and safety remain uncertain. This systematic review assessed the safety and efficacy of psilocybin for SUDs through a systematic database search conducted via OVID on May 22, 2024, and summarized 26 ongoing clinical trials registered on clinicaltrials.gov. Among 16...

Pharmacologic interventions for alcohol use disorder.

JAAPA June 1, 2025 Jordan Menge, Bernadette Evitt 2 citations

Alcohol use disorder (AUD) has devastating effects, and its prevalence in the US is growing. It is therefore important to examine multiple avenues for successful cessation and continued abstinence. Disulfiram, oral naltrexone, naltrexone IM, and acamprosate are currently the only four medications approved for the treatment of AUD by the FDA. This review aims to examine the efficacy of the...

Are Psychedelics Effective for Treating Substance Use Disorders?

May 28, 2025 David A. Gorelick

Current evidence remains insufficient to support the use of psychedelics for substance use disorders in routine clinical practice. Psilocybin has the most supportive data for alcohol use disorder, though it is of moderate quality. The evidence quality is generally low, with significant risk of bias due to poor blinding. Only half of identified studies were RCTs, with 44% conducted over 50 years...

Attitudes Toward Psychedelic Treatments by Individuals With Histories of Substance Use or Psychiatric Disorders: A Survey Study.

Journal of Addiction Medicine May 28, 2025 Sara Prostko, Alexander Wu, Samuel Maddams et al. 2 citations

Psychedelics may be promising treatments for substance use disorders (SUD). This study aims to understand how individuals with alcohol use disorder (AUD), opioid use disorder (OUD), and psychiatric disorders perceive and experience psychedelics for both nonmedical and medical use. Data for this cross-sectional survey study were collected from June 2023 to February 2024 at a large, tertiary...

DOI: 10.1097/adm.0000000000001517 (opens in new tab) Full text (opens in new tab) Substance use disorder Patient perceptions Psychedelic-assisted treatment Psychiatric disorders +6

The Potential Role of Psilocybin in Traumatic Brain Injury Recovery: A Narrative Review

Brain Sciences May 26, 2025 Charles Palmer, Ally T Ferber, Brian D Greenwald 4 citations

Background: This narrative review explores psilocybin’s potential use as a therapeutic agent in patients with traumatic brain injury (TBI). Methods: We engaged in a search of PubMed, ScienceDirect, and Cochrane’s databases for information on the effects of psilocybin. We also reviewed articles where psilocybin was used in patients with TBI. Articles from 2000–2025 were included. Results: A...

DOI: 10.3390/brainsci15060572 (opens in new tab) Neurogenesis Neuroplasticity Medical psilocybin Traumatic brain injury +12

The correlation between mindfulness and relapse prediction in individuals with substance use disorder: a cross-sectional study from Turkey.

Journal of ethnicity in substance abuse May 23, 2025 Sinem Aytop, Maral Kargin

The aim of this study is to examine the correlation between mindfulness and relapse prediction in individuals with substance use disorder. The study was conducted on individuals who were diagnosed with substance use disorders and were receiving at the psychiatry outpatient clinic of a university hospital in Turkey. In the study, 193 individuals with substance use disorders were reached. The...

Race/ethnicity moderates the associations between lifetime psilocybin use and opioid use disorder

PLoS One May 7, 2025 Grant Jones 2 citations

Background: Opioid use disorder (OUD) is a debilitating health condition that is associated with significant morbidity and mortality in the U.S. While preliminary studies have demonstrated that psilocybin is associated with lowered odds of OUD, current research in this domain suffers from a lack of investigation into the impact of race/ethnicity on this association. Objective: To assess the...

Evaluating the Effectiveness of Psychedelic-Assisted Therapy in Treating Alcohol Use Disorders: A Review

Alcoholism Treatment Quarterly May 2, 2025 Ritika Shah, Ashish Sarangi

ABSTRACT Background Alcohol Use Disorder (AUD) is a widespread condition with serious health, social, and economic impacts, often marked by relapse despite the availability of FDA-approved treatments. Recent studies suggest that psychedelic substances, such as psilocybin, Lysergic acid diethylamide (LSD), ayahuasca, etc. may offer novel therapeutic potential in treating AUD by modulating...

Exploratory Analysis on the Role of Video Tools and Multidisciplinary Healthcare Providers to Aid Counselling for Buprenorphine/Naloxone Induction Within the Evaluating Microdosing in the Emergency Department Study.

Cureus May 1, 2025 Alyssa Kong, Viseth Long, Elle Wang et al.

Introduction To address the rising deaths and hospitalizations related to opioid toxicity, buprenorphine/naloxone has been provided as a frontline treatment within the emergency department (ED), allowing increased access to opioid agonist therapies (OAT). However, several barriers exist toward initiating patients on buprenorphine/naloxone within the ED, such as shortages in healthcare staff and...

Recreational Ketamine Use among Individuals with Opioid Use Disorder: Demographics, Motivations, and Polysubstance Use.

Substance Use & Misuse May 1, 2025 Corinne L Chandler, Mance E Buttram, Matthew S Ellis 1 citation

Data show that recreational ketamine use appears to be increasing. This study aimed to understand how ketamine fits into broader polysubstance use in individuals with opioid use disorder (OUD). Survey data were collected from a sample of treatment-seeking individuals with OUD in March 2022. Of 301 respondents, 28.6% reported lifetime ketamine use. Ketamine use was more frequently reported among...

The intensity of the psychedelic experience is reliably associated with clinical improvements: A systematic review and meta-analysis.

Neuroscience & Biobehavioral Reviews May 1, 2025 Bruno Romeo, Ewen Kervadec, Baptiste Fauvel et al. 36 citations

Psychedelic-assisted therapies have demonstrated promising results in treating mental disorders, with results suggesting that the subjective intensity and quality of psychedelic experiences plays a significant role in mediating therapeutic effects. However, the strength of this association across diagnoses and treatment settings remains underexplored. We searched MEDLINE, Embase, and PsycINFO...

The landscape of ketamine use disorder: Patient experiences and perspectives on current treatment options.

Addiction April 28, 2025 Rebecca Harding, Tamsin Barton, Maeve Niepceron et al. 14 citations

To report the symptoms and aetiology of ketamine use disorder (KUD), gauge the effectiveness of current treatment services and identify strategies to enhance patient access and outcomes. Mixed-methods, cross-sectional questionnaire. Electronic survey from November 2023 to April 2024. Participants were recruited through snowball sampling, social media and referrals from UK addiction treatment...

DOI: 10.1111/add.70073 (opens in new tab) Full text (opens in new tab) Non‐treatment‐seeking abstinence Ketamine addiction Substance abuse treatment Global drug dependence +2

A Comparison of the Effectiveness of Group Counseling Based on Mindfulness-Based Cognitive Therapy and Metacognitive Therapy on Academic Procrastination and Internet Addiction among High School Students

پژوهش‌های کاربردی روانشناختی April 26, 2025 Hossein Ilanloo, Sedigheh Ahmadi, Kianoosh Zahrakar

The objective of the current investigation was to evaluate the efficacy of group counseling that is based on mindfulness-based cognitive therapy and metacognitive therapy in the context of academic procrastination and internet addiction among high school students. A control group was included in the study, which employed a quasi-experimental design with a pretest-posttest-follow-up approach...

DOI: 10.22059/japr.2025.337055.644161 (opens in new tab) Full text (opens in new tab) Academic procrastination Group counseling Internet addiction Metacognitive therapy +1

Narcolepsy and hallucinations in the spectrum of its manifestations. Clinical сase

Clinical review for general practice April 26, 2025 V. N. Grigoryeva, O. D. Elshina, П. Н. Николаев et al.

Narcolepsy is a rare chronic disorder characterized by impaired regulation of the sleep-wake cycle, which significantly worsens the quality of life of patients but is often diagnosed with considerable delay. Increasing physician awareness of this pathology can contribute to its earlier diagnosis and therapy optimization. A description and discussion of a clinical case of narcolepsy type 1 in a...

DOI: 10.47407/kr2025.6.4.00594 (opens in new tab) Addiction Narcolepsy Cataplexy Context archaeology +4

Drugs Used in "Chemsex"/Sexualized Drug Behaviour-Overview of the Related Clinical Psychopharmacological Issues.

Brain Sciences April 22, 2025 Fabrizio Schifano, Stefania Bonaccorso, Davide Arillotta et al. 14 citations

Background: "Chemsex" involves the intake of a range of drugs (e.g., synthetic cathinones, gamma-hydroxybutyric acid/gamma-butyrolactone (GHB/GBL), ketamine, methamphetamine, "poppers", type V phosphodiesterase (PDE) inhibitors, MDMA/ecstasy, cocaine, cannabis, and occasionally a few other molecules as well, to enhance and prolong sexual experiences. This paper aims to provide an overview of...

DOI: 10.3390/brainsci15050424 (opens in new tab) Full text (opens in new tab) Substance abuse Sexual health Chemsex Drug addiction +4

Adjunctive ketamine vs. buprenorphine in co-occurring major depressive disorder and opioid use disorder: a randomized, double-blind clinical trial assessing anxiety symptom severity and craving intensity.

Trials April 17, 2025 Arash Mansoori, Amir Bazrafshan, Jamshid Ahmadi et al. 4 citations

The concomitant presence of major depressive disorder (MDD) and opioid use disorder (OUD) poses a formidable clinical challenge, warranting effective interventions that address both psychiatric and addictive components. This study sought to compare the efficacy of adjunctive ketamine and buprenorphine in mitigating anxiety symptom severity and craving intensity in individuals with co-occurring...

Rare but relevant: Ketamine-induced cystitis - an in-depth review for addiction medicine.

Addiction April 4, 2025 Asem Abdelrahman, Mo Belal 4 citations

Ketamine-induced cystitis is an increasingly recognized complication associated with the addictive use of ketamine, a dissociative anesthetic. This article provides a comprehensive overview, focusing on its pathophysiology, clinical presentation, diagnosis, management strategies, and implications for addiction treatment. The British Association of Urological Surgeons consensus serves as a...

DOI: 10.1111/add.70052 (opens in new tab) Full text (opens in new tab) Ketamine bladder dysfunction Ketamine cystitis Ketamine uropathy Ureteric stricture +6